Aptose Biosciences Inc
APS
Company Profile
Business description
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
Contact
66 Wellington Street West
Suite 5300, TD Bank Tower Box 48
TorontoONM5K 1E6
CANT: +1 647 479-9828
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
13
Stocks News & Analysis
stocks
Telstra earnings: No need to get hysterical over mobile
Earnings report in-line with expectations.
stocks
Market Minute: RBA cuts rates again, US CPI data released
This week, the RBA cut rates after a surprise hold in July; CBA reported earnings ; US inflation data came out, showing its highest reading since February.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,220.40 | 8.30 | 0.09% |
| CAC 40 | 7,923.45 | 53.11 | 0.67% |
| DAX 40 | 24,359.30 | 18.20 | -0.07% |
| Dow JONES (US) | 44,946.12 | 34.86 | 0.08% |
| FTSE 100 | 9,138.90 | 38.34 | -0.42% |
| HKSE | 25,429.17 | 159.10 | 0.63% |
| NASDAQ | 21,622.98 | 87.69 | -0.40% |
| Nikkei 225 | 43,797.55 | 419.24 | 0.97% |
| NZX 50 Index | 12,970.64 | 81.26 | 0.63% |
| S&P 500 | 6,449.80 | 18.74 | -0.29% |
| S&P/ASX 200 | 8,947.30 | 8.70 | 0.10% |
| SSE Composite Index | 3,740.52 | 43.75 | 1.18% |